In Brief: Schering-Plough's Claritin
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Claritin: Prescription nonsedating antihistamine approved for use in the treatment of idiopathic chronic urticaria (hives), FDA notifies the company on Sept. 20. Claritin (loratadine) is the second nonsedating antihistamine to receive the hives indication after J&J's Hismanal (astemizole). Schering-Plough has touted Claritin as a top Rx-to-OTC switch candidate. The prescription drug generated $210 mil. in sales in the first half of 1995...